RSV immunoprophylaxis: Does the benefit justify the cost?

Pediatrics

Volumn 132, Issue 5, 2013, Pages 915-918

  Meissner, H Cody ^a   Kimberlin, David W ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Asthma; Palivizumab; Rsv prophylaxis; Viral respiratory infection

Indexed keywords

PALIVIZUMAB; PLACEBO; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

BRONCHIOLITIS; CHILDHOOD MORTALITY; COST BENEFIT ANALYSIS; HEALTH CARE COST; HOSPITALIZATION; HUMAN; IMMUNOPROPHYLAXIS; INCIDENCE; LOWER RESPIRATORY TRACT INFECTION; NONHUMAN; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TREATMENT OUTCOME; WHEEZING; ABNORMAL RESPIRATORY SOUND; DRUG EFFECTS; FEMALE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; MALE; PREMATURITY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; FEMALE; HUMANS; INFANT, PREMATURE; MALE; RESPIRATORY SOUNDS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 84887090291     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-2449     Document Type: Note

References (22)

1. Hall CB, Weinbberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588-598.
2. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by 13 years. Lancet. 1999;354(9178):541-545. (Pubitemid 29381367)
3. Sigurs N, Gustafsso PM, Bjarnason R, et al. Severe respiratory syncytial virus in early life and risk of wheeze and allergy by 13 years bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005;171(2):137-141. (Pubitemid 40105412)
4. Calişkan M, Bochkov YA, Kreiner-Møller E, et al. Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. N Engl J Med. 2013;368(15):1398-1407.
5. Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008;178(7):667-672.
6. Meissner HC, Long S. Respiratory syncytial virus in early life and risk of wheeze and allergy by 13 years infection and recurrent wheezing: A complex relationship. J Pediatr. 2007;151(1):6-7. (Pubitemid 46935181)
7. Yoshihara S, Kusuda S, Mochizuki H, Okada K, Nishima S, Simões EAF; C-CREW Investigators. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics. 2013;132(6):811-818.
8. Blanken MO, Robers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1794-1799.
9. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104(3):419-427. (Pubitemid 29424659)
10. IMpact-RSV study group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3): 531-537.
11. Feltes FF, Cabalk AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532-540. (Pubitemid 37352516)
12. Hasegawa K, Tsugawa Y, Brown DFM, Mansbach JM, Camargo CA Jr. Trends in bronchiolitis hospitalizations in the United States, 2000-2009. Pediatrics. 2013;132(1): 28-36.
13. Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic VV, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013;4: CD006602 10.1002/14651858.CD006602.pub4.
14. Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of RSV bronchiolitis in high-risk infants and young children: A systematic review and additional economic modeling of subgroup analyses. Health Technol Assess. 2011;15(5):1-140.
15. Weiner LB, Masaquel AS, Polak MJ, Mahadevia PJ. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. J Media Econ. 2012;15(5):997-1018.
16. Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: A national policy perspective. J Media Econ. 2012;15(5):987-996.
17. Hampp C, Kauf TL, Saidi AS, Winterstein AG. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med. 2011;165(6):498-505.
18. Wegner S, Vann JJ, Liu G, et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: Evidence from the North Carolina Medicaid Program. Pediatrics. 2004;114(6):1612-1619. (Pubitemid 41754927)
19. Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics. 2004;114(6):1606-1611. (Pubitemid 41754926)
20. Elhassan NO, Sorbero MES, Hall CB, Stevens TP, Dick AW. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med. 2006;160(10):1070-1076. (Pubitemid 44520638)
21. Owens DK, Qaseem A, Chou R, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions. Ann Intern Med. 2011;154(3):174-180.
22. Fuchs VR. The gross domestic product and health care spending. N Engl J Med. 2013; 369(2):107-109.